{"entity":{"id":"nct04912765","kind":"trial","name":"Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC","aka":[],"tldr":"A phase 2 trial of nivolumab in colorectal cancer, run by National Cancer Centre, Singapore, now recruiting.","summary":"Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC is a phase 2, interventional study registered as NCT04912765 by National Cancer Centre, Singapore, with a registry enrolment figure of 60 participants, started 2021-04-15 and due to reach its primary completion in 2026-12. Interventions recorded: Neoantigen Dendritic Cell Vaccine; Nivolumab. Conditions listed: Hepatocellular Carcinoma; Hepatocellular Cancer; Colorectal Cancer; Colorectal Carcinoma; Liver Metastases. Primary outcome: 24-month Relapse Free Survival; Induced immune response against vaccinated NAs. Colorectal eligibility wording from the registry: \"* Patients with histologically- or cytologically-diagnosed colorectal cancer with liver-limited metastases are eligible to enrol if:\". Sites: Singapore. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04912765","url":"https://clinicaltrials.gov/study/NCT04912765"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","neoantigen-mrna-vaccine"],"targets":[],"drugs":["nivolumab"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04912765","phase":"2","setting":"An Open Label, Single-arm, Phase II Neoantigen (NA) Dendritic Cell (DC) Vaccine and Anti-PD1 (Nivolumab) as Adjuvant Treatment in Resected Hepatocellular Carcinoma (HCC) (Group A) and Liver Metastases From Colorectal Cancer (CRLM) (Group B)","sponsor":"National Cancer Centre, Singapore","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04912765/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}